Figure 2 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam

Authors:
Open Access
Publisher website
Google Scholar
Abstract
RBM39 knockdown increased MRTX1719 responsiveness. A–C, PSN1 (A), MiaPaCa2 (B), and BxPc3 (C) cells were transfected with the indicated esiRNAs. Left, Western blot of RBM39 expression 72 hours after the transfection. β-Actin was used as the loading control. Right, quantification of RBM39 expression of (A) n = 6, (B) n = 5, and (C) n = 3 biological replicates. D–F, PSN1 (D), MiaPaCa2 (E), and BxPc3 (F) were transfected with the indicated siRNAs and treated after 24 hours with different dosages of MRTX1719 as indicated for additional 72 hours. Left, viability normalized to cells treated with the vehicle control and esiFLUC-transfected cells is depicted. Right, areas under the dose–response curves (AUC) were calculated and compared. Statistical significance was assessed using a two-tailed paired t test; *, P < 0.05 or the exact P value is indicated.